AOD-9604 During Pregnancy: What Every Woman Needs to Know

What Is AOD-9604 and Why Are Women Using It?

AOD-9604, formally called HGH fragment 176-191, is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone. Researchers isolated this fragment because it appears to retain the lipolytic (fat-burning) activity of full-length growth hormone without the insulin-desensitizing effects that make full GH problematic at weight-loss doses. In animal models, subcutaneous AOD-9604 reduced body fat in obese mice without affecting IGF-1 levels or fasting glucose, findings published in studies from the Monash University group in the early 2000s.

Women are using AOD-9604 primarily for adipose reduction, particularly in areas that resist diet and exercise. Compounding pharmacies licensed under FDA 503A regulations prepare it as an injectable peptide, typically dosed at 250 to 300 mcg subcutaneously once daily. Because it is not an FDA-approved drug, it carries no official prescribing label, no pregnancy category, and no lactation subsection, a critical distinction from approved pharmaceuticals.

Women in their reproductive years, including those with PCOS, postpartum weight retention, and perimenopausal metabolic changes, are among the populations most likely to seek weight-modifying peptide therapies. That overlap with reproductive and hormonal transitions makes pregnancy and lactation safety a non-negotiable conversation, not an afterthought.

How It Works: The Basic Mechanism

AOD-9604 binds to beta-3 adrenergic receptors in adipose tissue and activates hormone-sensitive lipase, stimulating fat breakdown. Unlike full-length growth hormone, it does not appear to stimulate the GH receptor at the pituitary level in short-term animal studies, which is why proponents argue it avoids the side effects of exogenous GH. Whether this receptor selectivity holds across the dramatic hormonal shifts of pregnancy, where GH-variant (placental GH) replaces pituitary GH from roughly 20 weeks gestation onward, is entirely unknown.

Why the Reproductive-Age Market Matters

Approximately 49% of pregnancies in the United States are unintended, meaning a woman using AOD-9604 for weight management may not know she is pregnant during the first trimester, the window of highest organogenesis risk. This is not a hypothetical concern. It is a clinical reality that shapes how every unapproved peptide must be counseled.

Pregnancy Safety: The Honest Answer

There is no human evidence that AOD-9604 is safe in pregnancy. There is also no human evidence that it causes harm. The absence of data is not the same as reassurance, and in pregnancy medicine, the default position for any agent without human safety data is avoidance.

No FDA Label, No Pregnancy Category

Because AOD-9604 has never received FDA approval, it was never assigned a pregnancy category under the old A/B/C/D/X system, nor has it been evaluated under the FDA Pregnancy and Lactation Labeling Rule (PLLR) that replaced letter categories in 2015. There is no prescribing label to consult. No package insert. No animal-to-human reproductive toxicology disclosure.

What the Animal Data Actually Show

The published animal research on AOD-9604 focused on obesity and metabolic endpoints, not reproductive toxicology. The landmark study by Heffernan and colleagues, published in 2001 in Molecular and Cellular Endocrinology, demonstrated fat reduction in obese Zucker rats but did not include pregnant animals or evaluate fetal outcomes. No teratogenicity studies, no embryotoxicity studies, and no developmental toxicology studies appear in the peer-reviewed literature for AOD-9604 specifically. What does not exist cannot be reassuring.

Placental Transfer: A Realistic Concern

Peptides cross the placenta via several mechanisms, including receptor-mediated endocytosis and paracellular diffusion, depending on molecular weight, charge, and protein binding. At 1,817 daltons, AOD-9604 is small enough that placental transfer cannot be assumed impossible. Growth hormone itself does not cross the placenta in meaningful amounts because it is a larger protein (22 kDa), but AOD-9604 is roughly 12 times smaller. No placental transfer studies for this peptide exist. ACOG guidance consistently advises that agents without human safety data be avoided in pregnancy, a position that directly applies here.

The Growth Hormone Pathway in Fetal Development

Fetal growth and placentation depend on a precisely regulated GH-IGF axis. Placental growth hormone (GH-V), encoded by the GH2 gene, progressively replaces pituitary GH from mid-pregnancy and drives maternal IGF-1 production, which in turn regulates fetal nutrient partitioning. Introducing an exogenous peptide that interacts with any part of this system, even partially, during a period of critical fetal programming carries theoretical risks that cannot currently be quantified. The first trimester, when fetal organs form, and the third trimester, when fetal adipose tissue and metabolic programming occur, are both biologically sensitive windows.

Breastfeeding and Lactation Safety

AOD-9604 has no entry in the NIH LactMed database, the standard reference for drug transfer into human milk. No studies have measured AOD-9604 concentrations in breast milk, and no infant exposure data exist.

Why Peptides in Breast Milk Matter

Many peptides are denatured in the gastrointestinal tract of a nursing infant and therefore do not reach systemic circulation in biologically active form. Insulin is the classic example. AOD-9604, however, has not been studied for oral bioavailability in infant GI physiology. Neonates have immature gut barriers, higher intestinal permeability, and different protease activity compared with adults. Whether AOD-9604 survives neonatal digestion intact is unknown. Given that the peptide is designed to act on adipose tissue and potentially on components of the GH axis, the theoretical consequence of systemic absorption in a breastfeeding infant, whose adipose and metabolic programming are still developing, warrants caution.

The LactMed Standard and What Its Silence Means

LactMed catalogues drugs with known lactation data and assigns risk ratings. A drug's absence from LactMed does not mean it is safe; it means no one has studied it. For compounded peptides like AOD-9604 that have never entered formal pharmaceutical development for humans, this data gap is expected and permanent unless someone funds dedicated lactation pharmacokinetic research, which is unlikely given the regulatory status of the compound.

Practical Guidance for Breastfeeding Women

Stop AOD-9604 before conceiving if breastfeeding is planned, and do not restart until breastfeeding has fully concluded. There is no defined washout period supported by evidence. Given a half-life estimated at two to three hours in animal pharmacokinetic models (no human PK data exist), a conservative clinical approach would be to discontinue at least 24 to 48 hours before nursing resumes after any accidental exposure, though this recommendation is extrapolated rather than evidence-based.

Who Should Not Use AOD-9604: Life-Stage Breakdown

The following framework is a WomanRx clinical synthesis based on reproductive life stage, not a published guideline. It is intended to help you identify where you fall and what conversation to have with your prescriber.

Trying to Conceive (Preconception)

Stop AOD-9604 before actively attempting conception. The preconception window, generally defined as three to six months before trying to conceive, is when you should review all medications and supplements with your OB-GYN or reproductive endocrinologist. ASRM guidelines on preconception care emphasize removing agents without established fetal safety profiles before pregnancy begins, not after a positive test.

First Trimester

Organogenesis, the formation of all major organ systems, occurs between weeks 3 and 10 of gestation. This is the highest-risk period for teratogenic exposure. Any woman who discovers she is pregnant while using AOD-9604 should discontinue immediately and notify her OB-GYN. A single exposure is unlikely to cause documented harm based on the biological half-life, but there is no human reassurance data to offer beyond that general reasoning.

Second and Third Trimesters

Fetal growth, brain development, and metabolic programming continue through all three trimesters. The second trimester brings rapid fetal adipose deposition, and a lipolytic peptide that modulates adipogenesis in animal models has no business being present in that environment without safety data. Third-trimester fetal insulin and GH-axis programming also represent a period of vulnerability.

Postpartum and Breastfeeding

Postpartum weight retention is real and distressing. Approximately 75% of women retain more than 2 kg at six months postpartum, and pressure to return to pre-pregnancy weight is a documented contributor to early breastfeeding cessation. That context makes peptide marketing to postpartum women particularly concerning. Until breastfeeding concludes completely, AOD-9604 should not be used.

Perimenopause

Women in perimenopause, the transition typically spanning 45 to 55 years of age, experience accelerating visceral adipose accumulation driven by declining estradiol. This is a population with genuine unmet need for adipose-modifying therapies. If pregnancy is not a possibility (confirmed by menstrual pattern, FSH levels, or age greater than 51 in a naturally menopausal woman), the pregnancy and lactation contraindications do not apply. Perimenopausal women should still understand that AOD-9604 lacks human efficacy data from large randomized controlled trials. The Metaboliq Phase IIb trial sponsored by Metabolic Pharmaceuticals evaluated oral AOD-9604 for obesity but was discontinued before Phase III, and the peptide never received regulatory approval. Perimenopausal use remains off-label and experimental regardless of pregnancy status.

Post-Menopause

Post-menopausal women have no pregnancy risk. The primary concerns shift to peptide quality from compounding pharmacies, injection site safety, and the absence of long-term human safety data for any population.

Contraception Requirements

Any woman using AOD-9604 who is of reproductive age and not actively trying to conceive should use reliable contraception. This is not a regulatory mandate (no approved label exists to mandate it), but it is sound clinical practice consistent with ACOG's Committee Opinion on medications and pregnancy planning.

Recommended contraceptive options for women on AOD-9604 therapy include long-acting reversible contraception (LARC), meaning an IUD (hormonal or copper) or subdermal implant, which eliminates adherence failure. Combined oral contraceptives are an alternative if no contraindication exists. Because AOD-9604 is often used alongside other peptides, compounds, or GLP-1 receptor agonists, confirm that no other agent in your regimen carries its own contraceptive interaction, teratogenicity warning, or fertility effect before settling on a method.

What the Evidence Gap Means for You

Women have been systematically underrepresented in pharmacological research for decades. A 2020 analysis in JAMA found that women remain underrepresented in phase I clinical trials, the earliest stage where pharmacokinetic and safety data are gathered. For unapproved compounded peptides like AOD-9604, this problem compounds: no clinical trials have enrolled women at any stage, pregnant or otherwise. Every dose recommendation you find online, every claimed safety profile, and every "no known harm" statement about AOD-9604 in women is extrapolated from obese-mouse data. That is the honest ceiling of what the evidence can support right now.

This gap is not unique to AOD-9604. Many peptides entering the compounding-pharmacy market are positioned ahead of the evidence. For women in reproductive years, the cost of that positioning is borne disproportionately.

Safer Alternatives by Life Stage

During Pregnancy

No weight-loss intervention is appropriate during pregnancy for women of normal or overweight BMI at conception. For women with obesity (BMI <30 at conception is protective; BMI >30 increases maternal and fetal risks), ACOG Practice Bulletin 156 recommends gestational weight gain targets rather than active weight loss. Nutritional counseling by a registered dietitian experienced in prenatal care is the first-line intervention.

Postpartum

For postpartum weight retention, evidence-supported strategies include resistance training, moderate caloric deficit, and exclusive breastfeeding, which is associated with approximately 0.5 kg per month of additional weight loss in some studies. FDA-approved GLP-1 receptor agonists such as semaglutide are contraindicated in pregnancy and lactation with a known label, meaning at least you have a defined contraindication rather than a data void.

Perimenopause and Menopause

For perimenopausal women seeking metabolic improvement, menopausal hormone therapy (MHT) has demonstrated reductions in visceral adipose accumulation, improved insulin sensitivity, and favorable effects on body composition in trials including the KEEPS trial. This is not an advertisement for MHT, which carries its own risk-benefit calculus, but it illustrates that evidence-supported options exist for the perimenopausal metabolic phenotype that AOD-9604 is being marketed to treat.

What to Tell Your Doctor

Bring this list to your next appointment if you are currently using AOD-9604 or considering it:

• Your current reproductive status and contraceptive method
• Whether you are planning pregnancy in the next 12 months
• All other peptides, compounds, supplements, and prescriptions in your current regimen
• Your reason for seeking adipose modification (PCOS, postpartum weight retention, perimenopausal visceral fat, or another cause), because the underlying condition may have an evidence-based treatment of its own
• Whether the compounding pharmacy you use is FDA-registered under 503A or 503B and whether the preparation has a certificate of analysis

A named clinician who dismisses your questions about pregnancy safety with "it should be fine" without citing data is not giving you adequate informed consent. You are entitled to a specific answer or an honest "we don't know."